Media Articles Related to Digitek (Digoxin)
Older Patients Taking Digoxin For Chronic Heart Failure At Reduced Risk For Hospital Admissions
Source: Medicare / Medicaid / SCHIP News From Medical News Today [2013.03.14]
Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction (HFrEF), according to research presented at the American College of Cardiology's 62nd Annual Scientific Session...
Heart Drug Digoxin Tied to Higher Death Risk for Some Patients
Source: MedicineNet Fainting Specialty [2012.11.29]
Title: Heart Drug Digoxin Tied to Higher Death Risk for Some Patients
Category: Health News
Created: 11/28/2012 12:35:00 PM
Last Editorial Review: 11/29/2012 12:00:00 AM
Congestive Heart Failure
Source: MedicineNet Myocarditis Specialty [2011.06.28]
Title: Congestive Heart Failure
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/28/2011 12:00:00 AM
Published Studies Related to Digitek (Digoxin)
The study of antiarrhythmic medications in infancy (SAMIS): a multicenter,
randomized controlled trial comparing the efficacy and safety of digoxin versus
propranolol for prophylaxis of supraventricular tachycardia in infants. 
CONCLUSIONS: There was no difference in SVT recurrence in infants treated with
Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. [2011.03]
The aim of this study was to investigate whether multiple doses of the oral and highly selective dipeptidyl peptidase-4 inhibitor linagliptin affect the steady-state pharmacokinetics of the P-glycoprotein substrate digoxin. This single-center, open-label, two-period cross-over study involved healthy subjects (n = 20), randomized to treatment sequence AB or BA, where A comprised 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days, and B comprised 0.25 mg digoxin qd for 11 days...
Digoxin for preventing or treating neonatal respiratory distress syndrome. [2011.01.19]
CONCLUSIONS: Although hemodynamic disturbances play a role in the overall pathogenesis of respiratory distress syndrome, the specific contribution of early congestive heart failure (unrelated to hemodynamically significant patent ductus arteriosus) does not appear to be a significant factor in RDS. Treatment with digoxin has no proven value in infants solely affected with RDS.
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). [2010.09]
Several retrospective studies have raised concerns regarding digoxin therapy in select subgroups of heart failure patients... No benefit with digoxin use was observed in this study, underscoring the need to reassess the role of digoxin in the contemporary management of heart failure.
Digoxin immune fab treatment for severe preeclampsia. [2010.09]
We evaluated the efficacy, safety, and biological mechanisms of digoxin immune Fab (DIF) treatment of severe preeclampsia. Fifty-one severe preeclamptic patients were randomized in double-blind fashion to DIF ( N = 24) or placebo ( N = 27) for 48 hours...
Clinical Trials Related to Digitek (Digoxin)
A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults [Recruiting]
The primary objective of this study is to determine the effect of repeat oral doses of
eliglustat 150 mg twice daily (BID) (or 100 mg BID for CYP2D6 poor metabolizers) on the
pharmacokinetics (PK) of orally administered digoxin 0. 25 mg in healthy adult subjects. This
will be a single-site, open-label study in 2 staggered cohorts of healthy adult subjects.
The study will comprise a screening period (between Day - 45 and Day -2), treatment period 1
(Day - 1 to Day 4), treatment period 2 (Day 11 to Day 18), and a safety follow-up visit (Day
24 ± 1). There will be a 10-day washout between dosing of study drug in Period 1 and Period
2. The duration of each subject's participation in the study, inclusive of the screening and
follow-up visits, will be approximately 10 weeks.
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients [Recruiting]
The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics
(PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
A Trial of Digoxin Before Second-Trimester Abortion [Recruiting]
Digoxin Withdrawal in Stable Heart Failure [Recruiting]
Heart failure is a chronic condition in which the heart fails to function as a pump to move
blood around the body. This sets up a complex physiologic response to compensate, which
include activation of many hormonal mechanisms which result in fluid accumulation.
In recent years, medications to block the hormonal response to heart failure are given as
standard drugs, and these include ACE inhibitors, and beta blockers. Mortality is reduced
with these medications, as well as symptoms improved.
Medications that were traditionally used in heart failure include diuretics, which cause
fluid loss, and digoxin, which causes the heart to pump harder. These medications were
introduced before clinical trials as we know them now were run. Since the introduction of
ACE inhibitors and beta blockers, it is not clear whether there is still a role for digoxin.
In this study, we plan to withdraw digoxin from patients with stable heart failure in normal
rhythm, taking stable doses of ACE inhibitors and beta blockers, in a closely monitored
environment and watch for the effect of this on heart failure.
Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin [Recruiting]